IFNA1 and COVID-19: Specifically, the IFN pathway appears to be implicated through many of the identified variants indicated in the database articles, as identified previously in the innate immune response to SARS-CoV-2 [11, 20, 33], and IFN therapy has already been used in clinical trials for COVID-19 patients who present with severe disease and is currently an approved therapeutic drug.